Company
Predictive Oncology Inc.
NASDAQ:POAI
Predictive Oncology Inc is a knowledge-driven company focused on applying artificial intelligence (AI) to the research and development process of personalized cancer therapies, which can lead to better treatments, improved patient outcomes and faster time to market. By utilizing its flagship AI-powered drug discovery platform, Predictive Oncology can analyze well-characterized patient tumor databases from multiple cancer types against a variety of drug compounds. The company's AI engine takes a multiomic approach, which considers the vast multitude of factors that make each cancer unique, in the prediction of responders and non-responders by tumor and drug type. The output provides a set of tumor types and drug compounds that are more likely to succeed in clinical development and ultimately succeed in optimal therapy selection for patients.
34 stories · page 1 of 2
Predictive Oncology reports 45% revenue jump, increased gross profit margin in 3Q
The company said during the quarter it leveraged its novel artificial intelligence-powered platform paired with the largest privately held biobank of more than 150,000 tumor samples to help drug developers make higher confidence predictions
Predictive Oncology strengthens board of directors with life sciences and corporate attorney David Smith
The Minnesota-based biotech company cited Smith’s “extensive transactional experience, venture financings and regulatory matters” for life sciences companies and investors